Tsubota Laboratory Incorporated Logo

Tsubota Laboratory Incorporated

R&D company developing treatments for ophthalmology and CNS disorders.

4890 | T

Overview

Corporate Details

ISIN(s):
JP3535700003
LEI:
Country:
Japan
Address:
新宿区信濃町35 慶應義塾大学信濃町キャンパス2号館9階CRIK信濃町E7

Description

Tsubota Laboratory Incorporated is a research and development company that originated as a startup from Keio University. It is engaged in the creation of pharmaceuticals and medical devices. The company's primary focus is on ophthalmology, developing solutions for conditions such as myopia, dry eye, and presbyopia. Additionally, it explores treatments for central nervous system (CNS) disorders and brain diseases. The corporate strategy centers on out-licensing its developed pipelines to commercial partners. A notable pipeline is a therapeutic candidate designed to curtail the progression of myopia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:34
確認書
Japanese 9.0 KB
2025-11-12 07:33
半期報告書-第14期(2025/04/01-2026/03/31)
Japanese 195.3 KB
2025-06-27 04:35
臨時報告書
Japanese 23.3 KB
2025-06-26 09:02
確認書
Japanese 9.4 KB
2025-06-26 09:01
内部統制報告書-第13期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-26 09:01
有価証券報告書-第13期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 08:02
確認書
Japanese 9.0 KB
2024-11-14 08:02
半期報告書-第13期(2024/04/01-2025/03/31)
Japanese 201.7 KB
2024-06-27 04:10
内部統制報告書-第12期(2023/04/01-2024/03/31)
Japanese 22.8 KB
2024-06-27 04:09
確認書
Japanese 8.9 KB
2024-06-27 04:08
有価証券報告書-第12期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-02-14 07:11
確認書
Japanese 9.0 KB
2024-02-14 07:10
四半期報告書-第12期第3四半期(2023/10/01-2023/12/31)
Japanese 160.1 KB
2023-11-13 07:06
確認書
Japanese 9.0 KB
2023-11-13 07:02
四半期報告書-第12期第2四半期(2023/07/01-2023/09/30)
Japanese 193.0 KB

Automate Your Workflow. Get a real-time feed of all Tsubota Laboratory Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tsubota Laboratory Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tsubota Laboratory Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BioSenic SA Logo
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
Belgium
BIOS
BIOTECH Logo
A biotechnology group offering preclinical services, intein development, and licensing.
Spain
BST
Biovica International B Logo
Develops blood-based biomarker assays for cancer therapy monitoring.
Sweden
BIOVIC
Bonus BioGroup Ltd. Logo
A clinical-stage biotech firm developing cell therapy and tissue engineering products.
Israel
BONS
BRAIN Biotech AG Logo
Develops enzymes and microorganisms for the food, chemical, and life sciences sectors.
Germany
BNN
BriaCell Therapeutics Corp. Logo
Clinical-stage immuno-oncology company developing cellular immunotherapies for cancer.
United States of America
BCTX
BSF ENTERPRISE PLC Logo
Develops cell-based solutions for cultivated meat, leather, and corneal repair.
United Kingdom
BSFA
BullFrog AI Holdings, Inc. Logo
A technology company applying AI and machine learning to drug development.
United States of America
BFRG
Burning Rock Biotech Ltd Logo
A global diagnostics company specializing in precision oncology using NGS technology.
United States of America
BNR
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for B cell-mediated autoimmune diseases.
United States of America
CABA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.